Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

D. Hughes; E. Faulkner; L. Annemans; L. Garrison; M. Helfand; A.P. Holtorf; J. Hornberger; D.A. Hughes; T. Li; D. Malone; K. Payne; U. Siebert; A. Towse; D. Veenstra; J. Watkins

doi:10.1016/j.jval.2012.05.006

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

D. Hughes, E. Faulkner, L. Annemans, L. Garrison, M. Helfand, A.P. Holtorf, J. Hornberger, D.A. Hughes, T. Li, D. Malone, K. Payne, U. Siebert, A. Towse, D. Veenstra, J. Watkins

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1162-1171
Journal	Value in Health
Volume	15
Issue number	8
DOIs	https://doi.org/10.1016/j.jval.2012.05.006
Publication status	Published - 1 Dec 2012

Access to Document

10.1016/j.jval.2012.05.006

Cite this

Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D., & Watkins, J. (2012). Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 15(8), 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

@article{aa0dfb3e0a9f45609c4a35da46fc19d8,

title = "Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group",

author = "D. Hughes and E. Faulkner and L. Annemans and L. Garrison and M. Helfand and A.P. Holtorf and J. Hornberger and D.A. Hughes and T. Li and D. Malone and K. Payne and U. Siebert and A. Towse and D. Veenstra and J. Watkins",

year = "2012",

month = dec,

day = "1",

doi = "10.1016/j.jval.2012.05.006",

language = "English",

volume = "15",

pages = "1162--1171",

journal = "Value in Health",

issn = "1524-4733",

publisher = "Elsevier",

number = "8",

}

Hughes, D, Faulkner, E, Annemans, L, Garrison, L, Helfand, M, Holtorf, AP, Hornberger, J, Hughes, DA, Li, T, Malone, D, Payne, K, Siebert, U, Towse, A, Veenstra, D & Watkins, J 2012, 'Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group', Value in Health, vol. 15, no. 8, pp. 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. / Hughes, D.; Faulkner, E.; Annemans, L. et al.
In: Value in Health, Vol. 15, No. 8, 01.12.2012, p. 1162-1171.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

AU - Hughes, D.

AU - Faulkner, E.

AU - Annemans, L.

AU - Garrison, L.

AU - Helfand, M.

AU - Holtorf, A.P.

AU - Hornberger, J.

AU - Hughes, D.A.

AU - Li, T.

AU - Malone, D.

AU - Payne, K.

AU - Siebert, U.

AU - Towse, A.

AU - Veenstra, D.

AU - Watkins, J.

PY - 2012/12/1

Y1 - 2012/12/1

U2 - 10.1016/j.jval.2012.05.006

DO - 10.1016/j.jval.2012.05.006

M3 - Article

SN - 1524-4733

VL - 15

SP - 1162

EP - 1171

JO - Value in Health

JF - Value in Health

IS - 8

ER -

Hughes D, Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012 Dec 1;15(8):1162-1171. doi: 10.1016/j.jval.2012.05.006